Literature DB >> 8632751

RS-17053 (N-[2-(2-cyclopropylmethoxyphenoxy)ethyl]-5-chloro-alpha, alpha-dimethyl-1H-indole-3-ethanamine hydrochloride), a selective alpha 1A-adrenoceptor antagonist, displays low affinity for functional alpha 1-adrenoceptors in human prostate: implications for adrenoceptor classification.

A P Ford1, N F Arredondo, D R Blue, D W Bonhaus, J Jasper, M S Kava, J Lesnick, J R Pfister, I A Shieh, R L Vimont, T J Williams, J E McNeal, T A Stamey, D E Clarke.   

Abstract

Norepinephrine (NE) contracts smooth muscle cells within the human lower urinary tract (LUT) (bladder neck, prostate, and urethra). Receptor distribution and pharmacological evidence have implicated activation of alpha 1A-adrenoceptors. We disclose the pharmacological properties of the novel, selective alpha 1A-adrenoceptor antagonist N-[2-(2-cyclopropylmethoxyphenoxy)ethyl]-5-chloro- alpha,alpha-dimethyl-1H-indole-3-ethanamine hydrochloride (RS-17053) and examine critically the pharmacological identity of the alpha 1-adrenoceptor mediating contractions to NE in human LUT tissues. In several tissues from rat and cloned adrenoceptors, RS-17053 displayed high affinity for the alpha 1A-adrenoceptor (pKi and pA2 estimates of 9.1-9.9) and a 30-100-fold selectivity over the alpha 1B- and the alpha 1D-adrenoceptor subtypes (pK1 and pA2 estimates of 7.7-7.8). However, in isolated smooth muscle preparations from human LUT tissues, RS-17053 antagonized responses to NE only at high concentrations. Estimates of affinity (pA2) at alpha 1-adrenoceptors mediating NE-induced contractions were 7.5 in prostatic periurethral longitudinal smooth muscle (compared with 8.6 for prazosin), 6.9 in anterior fibromuscular stroma (prazosin, 8.9), and 7.1 in bladder neck (prazosin, 8.5). These findings indicate that contractile responses to NE in human LUT tissues are mediated by a receptor displaying pharmacological properties that are clearly different from those of the defined alpha 1A-adrenoceptor and raise the possibility that multiple forms of the alpha 1A-adrenoceptor may exist in human LUT that are discriminated by RS-17053. In this regard, the affinity estimates obtained with RS-17053 and other alpha 1-adrenoceptor antagonists in human LUT tissues are identical to those described for the putative alpha 1L-adrenoceptor.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8632751

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  31 in total

1.  Pharmacological analysis of the novel, selective alpha1-adrenoceptor antagonist, KMD-3213, and its suitability as a tritiated radioligand.

Authors:  S Murata; T Taniguchi; I Muramatsu
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

2.  Investigation of the subtypes of alpha1-adrenoceptor mediating contractions of rat vas deferens.

Authors:  V Honner; J R Docherty
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

3.  Discrimination by SZL49 between contractions evoked by noradrenaline in longitudinal and circular muscle of human vas deferens.

Authors:  Nnaemeka I B Amobi; John Guillebaud; A V Kaisary; Eileen Turner; I Christopher H Smith
Journal:  Br J Pharmacol       Date:  2002-05       Impact factor: 8.739

4.  Activation of alpha(1) -adrenergic receptors stimulate the growth of small mouse cholangiocytes via calcium-dependent activation of nuclear factor of activated T cells 2 and specificity protein 1.

Authors:  Gianfranco Alpini; Antonio Franchitto; Sharon Demorrow; Paolo Onori; Eugenio Gaudio; Candace Wise; Heather Francis; Julie Venter; Shelley Kopriva; Romina Mancinelli; Guido Carpino; Franco Stagnitti; Yoshiyuki Ueno; Yuyan Han; Fanyin Meng; Shannon Glaser
Journal:  Hepatology       Date:  2011-01-03       Impact factor: 17.425

5.  Correlation between vasoconstrictor roles and mRNA expression of alpha1-adrenoceptor subtypes in blood vessels of genetically engineered mice.

Authors:  Chihiro Hosoda; Akito Tanoue; Mari Shibano; Yoshio Tanaka; Masami Hiroyama; Taka-aki Koshimizu; Susanna Cotecchia; Tadaichi Kitamura; Gozoh Tsujimoto; Katsuo Koike
Journal:  Br J Pharmacol       Date:  2005-10       Impact factor: 8.739

6.  The effects of SB 216469, an antagonist which discriminates between the alpha 1A-adrenoceptor and the human prostatic alpha 1-adrenoceptor.

Authors:  R Chess-Williams; C R Chapple; F Verfurth; A J Noble; C J Couldwell; M C Michel
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

7.  Agonist pharmacology at recombinant α1A - and α1L -adrenoceptors and in lower urinary tract α1 -adrenoceptors.

Authors:  Hatsumi Yoshiki; Junsuke Uwada; Hidenori Umada; Tadashi Kobayashi; Toshihiro Takahashi; Tomio Yamakawa; Akio Yamaguchi; Osamu Yokoyama; Ikunobu Muramatsu
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 8.739

8.  Identification of the alpha1L-adrenoceptor in rat cerebral cortex and possible relationship between alpha1L- and alpha1A-adrenoceptors.

Authors:  S Morishima; F Suzuki; H Yoshiki; A S Md Anisuzzaman; Z S Sathi; T Tanaka; I Muramatsu
Journal:  Br J Pharmacol       Date:  2008-01-28       Impact factor: 8.739

Review 9.  Subtypes of functional alpha1-adrenoceptor.

Authors:  James R Docherty
Journal:  Cell Mol Life Sci       Date:  2009-10-28       Impact factor: 9.261

10.  Evaluation of alpha1-adrenoceptors in the rabbit iris: pharmacological characterization and expression of mRNA.

Authors:  S Nakamura; T Taniguchi; F Suzuki; Y Akagi; I Muramatsu
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.